ExoCoBio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 104

Employees

  • Latest Deal Type
  • 2ndary - Private
  • (In Progress)

  • Latest Deal Amount
  • $71.9K

  • Investors
  • 21

ExoCoBio General Information

Description

Developer of regenerative medicine and biopharmaceuticals designed to create value for the healthy life of mankind. The company's products specialize in the development of stem cell-derived exosome therapeutics which are nano-vesicles secreted by cells for intercellular signalings for the growth of skin and hair, enabling clinicians to develop stimulation of cellular tissue regeneration technology alternatives.

Contact Information

Website
exocobio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 18th Daeryung Techno Town
  • 19, Gasan digital 1-ro, Geumcheon-gu
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 18th Daeryung Techno Town
  • 19, Gasan digital 1-ro, Geumcheon-gu
  • Seoul
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ExoCoBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 12-Sep-2025 $71.9K In Progress Profitable
5. Later Stage VC (Series C) 02-Nov-2023 Completed Generating Revenue
4. Later Stage VC (Series C) 25-Aug-2020 Completed Generating Revenue
3. Early Stage VC (Series B) 12-Sep-2018 Completed Startup
2. Early Stage VC $8M $19M Completed Startup
1. Early Stage VC (Series A) 02-May-2017 $11M $11M Completed Startup
To view ExoCoBio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ExoCoBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of regenerative medicine and biopharmaceuticals designed to create value for the healthy life of mankind. The
Drug Discovery
Seoul, South Korea
104 As of 2023

San Ramon, CA
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ExoCoBio Competitors (30)

One of ExoCoBio’s 30 competitors is Histogen, a Formerly VC-backed company based in San Ramon, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Histogen Formerly VC-backed San Ramon, CA
PIPr Therapeutics Venture Capital-Backed Durham, NC
S-Biomedic Formerly VC-backed Ghent, Belgium
Azitra Formerly VC-backed Branford, CT
Aquapharm Biodiscovery Formerly VC-backed Oban, United Kingdom
You’re viewing 5 of 30 competitors. Get the full list »

ExoCoBio Patents

ExoCoBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025037785-A1 Novel composition comprising actinidia polygama-derived exosomes as active ingredient Inactive 11-Aug-2023
EP-4663749-A1 Method for promoting secretion of exosomes from animal cells by using rose-derived exosomes Pending 30-Mar-2023
EP-4663749-A4 Method for promoting secretion of exosomes from animal cells by using rose-derived exosomes Pending 30-Mar-2023
US-20250368951-A1 Method for promoting secretion of exosomes from animal cells by using rose-derived exosomes Pending 30-Mar-2023
WO-2024204971-A1 Method for promoting secretion of exosomes from animal cells by using rose-derived exosomes Inactive 30-Mar-2023 C12N5/0667
To view ExoCoBio’s complete patent history, request access »

ExoCoBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ExoCoBio Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hana S&B Investment PE/Buyout Majority
TKG Ventures Venture Capital Minority
Focus Assets Management Asset Manager Minority
G.N. Tech Venture Capital Venture Capital Minority
HLB bioStep Company Corporation Minority
You’re viewing 5 of 21 investors. Get the full list »

ExoCoBio Acquisitions (1)

ExoCoBio’s most recent deal was a Merger/Acquisition with BENEV. The deal was made on 12-Jul-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
BENEV 12-Jul-2023 Merger/Acquisition Other Devices and Supplies
To view ExoCoBio’s complete acquisitions history, request access »

ExoCoBio Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
BENEV Mission Viejo, CA 2000

ExoCoBio FAQs

  • When was ExoCoBio founded?

    ExoCoBio was founded in 2017.

  • Where is ExoCoBio headquartered?

    ExoCoBio is headquartered in Seoul, South Korea.

  • What is the size of ExoCoBio?

    ExoCoBio has 104 total employees.

  • What industry is ExoCoBio in?

    ExoCoBio’s primary industry is Drug Discovery.

  • Is ExoCoBio a private or public company?

    ExoCoBio is a Private company.

  • What is the current valuation of ExoCoBio?

    The current valuation of ExoCoBio is .

  • What is ExoCoBio’s current revenue?

    The current revenue for ExoCoBio is .

  • How much funding has ExoCoBio raised over time?

    ExoCoBio has raised $55.3M.

  • Who are ExoCoBio’s investors?

    Hana S&B Investment, TKG Ventures, Focus Assets Management, G.N. Tech Venture Capital, and HLB bioStep Company are 5 of 21 investors who have invested in ExoCoBio.

  • Who are ExoCoBio’s competitors?

    Histogen, PIPr Therapeutics, S-Biomedic, Azitra, and Aquapharm Biodiscovery are some of the 30 competitors of ExoCoBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process